Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead to a novel therapy principle for the treatment of diabesity. Here, we report a series of novel peptides with dual activity on these receptors that were discovered by rational design. On the basis of sequence analysis and structure-based design, structural elements of glucagon were engineered into the selective GLP-1 receptor agonist exendin-4, resulting in hybrid peptides with potent dual GLP-1/glucagon receptor activity. Detailed structure-activity relationship data are shown. Further modifications with unnatural and modified amino acids resulted in novel metabolically stable peptides that demonstrated a significant dose-dependent decrease in blood glucose in chronic studies in diabetic db/db mice and reduced body weight in diet-induced obese (DIO) mice. Structural analysis by NMR spectroscopy confirmed that the peptides maintain an exendin-4-like structure with its characteristic tryptophan-cage fold motif that is responsible for favorable chemical and physical stability.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
A hierarchical approach to all‐atom protein loop prediction
Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J. F., Honig, B., Shaw, D. E., & Friesner, R. A. (2004) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10613 · Cited by 2,504
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Designing a 20-residue protein
Neidigh, J. W., Fesinmeyer, R. M., & Andersen, N. H. (2002) · Nature Structural Biology · doi:10.1038/nsb798 · Cited by 793
A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis
KING, D. S., FIELDS, C. G., & FIELDS, G. B. (1990) · International Journal of Peptide and Protein Research · doi:10.1111/j.1399-3011.1990.tb00976.x · Cited by 725
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
Research works printed but not linked: 1
- Pegapamodutide, C16H27N3O7S, PubChem.https://pubchem.ncbi.nlm.nih.gov/compound/121494121#section=Chemical-and-Physical-Properties(accessed Mar 21, 2017) .
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Glucagon Receptor Signaling and Lipid Metabolism
Galsgaard, K. D., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00413 · Cited by 218
Glucagon Receptor Signaling and Glucagon Resistance
Janah, L., Kjeldsen, S., Galsgaard, K. D., Winther-Sørensen, M., Stojanovska, E., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133314 · Cited by 203
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
“3) and their efficacy translates from obese rodents to nonhuman primates and humans (Day et al., 2009; Pocai et al., 2009; Henderson et al., 2016; Tschop et al., 2016; Evers et al., 2017).”
BackgroundGLP-1: Molecular mechanisms and outcomes of a complex signaling system
Smith, N. K., Hackett, T. A., Galli, A., & Flynn, C. R. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.04.010 · Cited by 188
“, 2009), substantial progress has been made in producing these polyagonists, utilizing previous successful strategies including lipidation and building off the exendin backbone(Evers et al., 2017; Finan et al., 2013).”
BackgroundBossart, M., Wagner, M., Elvert, R., Evers, A., Hübschle, T., Kloeckener, T., Lorenz, K., Moessinger, C., Eriksson, O., Velikyan, I., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.005 · Cited by 179
Self-citationTillner, J., Posch, M. G., Wagner, F., Teichert, L., Hijazi, Y., Einig, C., Keil, S., Haack, T., Wagner, M., Bossart, M., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13494 · Cited by 164
“Based on the clinical potential of GLP-1R and GCR dual agonism and available data for other dual agonists, we synthesized novel drug candidates with higher in vitro potency for the GLP1R than for the GCR and investigated their effects on weight loss compared with pure GLP-1RAs.(35) It has been reported that the right…”
MethodSelf-citationTargeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Glucagon Regulation of Energy Expenditure
Kleinert, M., Sachs, S., Habegger, K. M., Hofmann, S. M., & Müller, T. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215407 · Cited by 147
Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug–Target Interactions
Lu, S., & Zhang, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01844 · Cited by 158
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Clemmensen, C., Finan, B., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Hofmann, S. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0118-x · Cited by 134
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Gut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 111
“In DIO mice, a twice daily treatment with 50 μg/kg of this coagonist showed significant glucose lowering effects with associated body weight and body fat mass reduction in murine models of diabetes and obesity over a treatment period of 33 days [172].”
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Alavi, S. E., Cabot, P. J., & Moyle, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00308 · Cited by 95
Glucagon Control on Food Intake and Energy Balance
Al-Massadi, O., Fernø, J., Diéguez, C., Nogueiras, R., & Quiñones, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163905 · Cited by 88
Cheang, J. Y., & Moyle, P. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201700781 · Cited by 82
The molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
Hope, D. C. D., Vincent, M. L., & Tan, T. M. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735019 · Cited by 81
“5% increase in HbA1C over 32 days seen in the vehicle control treated group (78).”
BackgroundYap, M. K. K., & Misuan, N. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13169 · Cited by 77
Unnatural helical peptidic foldamers as protein segment mimics
Sang, P., & Cai, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00395c · Cited by 83
Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.04.034 · Cited by 85
New Insights into the Structure and Function of Class B1 GPCRs
Cary, B. P., Zhang, X., Cao, J., Johnson, R. M., Piper, S. J., Gerrard, E. J., Wootten, D. L., & Sexton, P. M. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac033 · Cited by 77
Evers, A., Bossart, M., Pfeiffer-Marek, S., Elvert, R., Schreuder, H., Kurz, M., Stengelin, S., Lorenz, M., Herling, A., Konkar, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00292 · Cited by 50
Self-citationKnerr, P. J., Mowery, S. A., Finan, B., Perez-Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2020) · Peptides · doi:10.1016/j.peptides.2019.170225 · Cited by 49
Eriksson, O., Haack, T., Hijazi, Y., Teichert, L., Tavernier, V., Laitinen, I., Berglund, J. E., Antoni, G., Velikyan, I., Johansson, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73815-5 · Cited by 46
Self-citationStructural analysis of the dual agonism at GLP-1R and GCGR
Li, Y., Zhou, Q., Dai, A., Zhao, F., Chang, R., Ying, T., Wu, B., Yang, D., Wang, M., & Cong, Z. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303696120 · Cited by 50
“SAR425899 is a palmitoylated chimeric peptide derived from selective mutation of exendin-4 (20, 21), with a similar in vitro potency ratio at the two receptors as observed in MEDI0382 (22).”
Elvert, R., Herling, A. W., Bossart, M., Weiss, T., Zhang, B., Wenski, P., Wandschneider, J., Kleutsch, S., Butty, U., Kannt, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13212 · Cited by 42
Self-citationMachine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
Puszkarska, A. M., Taddese, B., Revell, J. D., Davies, G., Field, J., Hornigold, D. C., Buchanan, A. G., Vaughan, T. J., & Colwell, L. J. (2024) · Nature Chemistry · doi:10.1038/s41557-024-01532-x · Cited by 46
“The design of high-potency unimo-lecular GCGR/GLP-1R dual agonists has revolved around substitutions in the mid and C-terminal segments of proposed analogues 5,14–16 .”
Chepurny, O. G., Matsoukas, M.-T., Liapakis, G., Leech, C. A., Milliken, B. T., Doyle, R. P., & Holz, G. G. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005682 · Cited by 41
“Consistent with a prior report concerning glucagon action at the GLP-1R (5), high concentrations of glucagon (1–100 nM) raised levels of cAMP in HEK293GLP-1R cells expressing the human GLP-1R (Fig.”
BackgroundInsights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
Méndez, M. M., Matter, H., Defoßa, E., Kurz, M. E., Lebreton, S., Li, Z., Lohmann, M., Löhn, M., Mors, H., Podeschwa, M. A. L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01071 · Cited by 38
Self-citationIncretin combination therapy for the treatment of non-alcoholic steatohepatitis
Kannt, A., Madsen, A. N., Kammermeier, C., Elvert, R., Klöckener, T., Bossart, M., Haack, T., Evers, A., Lorenz, K., Hennerici, W., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14035 · Cited by 37
“Gene expression was quantified using digital droplet PCR analysis as described.(21)”
MethodSelf-citationAdvances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics
Velikyan, I., & Eriksson, O. (2019) · Theranostics · doi:10.7150/thno.38366 · Cited by 40
“combining activity for both GLP-1 and the glucagon receptor or the gastric inhibitory polypeptide (GIP) receptor [15-18].”
BackgroundSimonsen, L., Lau, J., Kruse, T., Guo, T., McGuire, J., Jeppesen, J. F., Niss, K., Sauerberg, P., Raun, K., & Dornonville de la Cour, C. (2022) · PLOS ONE · doi:10.1371/journal.pone.0264974 · Cited by 36
Glucagon-based therapy: Past, present and future
Patil, M., Deshmukh, N., Patel, M. V., & Sangle, G. V. (2020) · Peptides · doi:10.1016/j.peptides.2020.170296 · Cited by 37
Evers, A., Clénet, D., & Pfeiffer‐Marek, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020375 · Cited by 42
“Following analysis of 3D structural models based on the known X-ray structures of GLP-1, GIP, and GCG in their respective receptors [20,42,43], amino acids of the natural hormones have been introduced into specific positions of exendin-4 to achieve a balanced in vitro activity profile at the different receptors.”
MethodSelf-citationSindhikara, D., Wagner, M., Gkeka, P., Güssregen, S., Tiwari, G., Heßler, G., Yapici, E., Li, Z., & Evers, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01500 · Cited by 37
Self-citationRevisiting amino acids and peptides as anti-glycation agents
Chilukuri, H., Kulkarni, M. J., & Fernandes, M. (2018) · MedChemComm · doi:10.1039/c7md00514h · Cited by 38
Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors
Darbalaei, S., Yuliantie, E., Dai, A., Chang, R., Zhao, P., Yang, D., Wang, M.-W., Sexton, P. M., & Wootten, D. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114150 · Cited by 33
A GLP‐1/glucagon (GCG)/CCK2 receptors tri‐agonist provides new therapy for obesity and diabetes
Zhao, S., Yan, Z., Du, Y., Li, Z., Tang, C., Jing, L., Sun, L., Yang, Q., Tang, X., Yuan, Y., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15860 · Cited by 30
“The xGLP/GCG/gastrin was synthesized using Fmoc solid phase peptide synthesis (SPPS) strategy, as previously described (Evers et al., 2017).”
BackgroundMethodPelle, M. C., Provenzano, M., Zaffina, I., Pujia, R., Giofrè, F., Lucà, S., Andreucci, M., Sciacqua, A., & Arturi, F. (2021) · Life · doi:10.3390/life12010029 · Cited by 28
Are peptide conjugates the golden therapy against obesity?
Brandt, S. J., Kleinert, M., Tschöp, M. H., & Müller, T. D. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0264 · Cited by 27
Chen, X., Fu, J., Zhou, F. L., Yang, Q., Wang, J., Feng, H., Jiang, W., Jin, L., Tang, X., Jiang, N., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00736 · Cited by 26
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Optimization of peptide-based polyagonists for treatment of diabetes and obesity
Knerr, P. J., Finan, B., Gelfanov, V. M., Pérez–Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.047 · Cited by 24
Elvert, R., Bossart, M., Herling, A. W., Weiss, T., Zhang, B., Kannt, A., Wagner, M., Haack, T., Evers, A., Dudda, A., et al. (2018) · Endocrinology · doi:10.1210/en.2018-00399 · Cited by 24
Self-citationFirst-in-class positron emission tomography tracer for the glucagon receptor
Velikyan, I., Haack, T., Bossart, M., Evers, A., Laitinen, I., Larsen, P. J., Plettenburg, O., Johansson, L., Pierrou, S. E., Wagner, M., et al. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0482-0 · Cited by 21
Self-citationCui, J., Shang, A., Wang, W., & Chen, W. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118339 · Cited by 20
Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
Usui, R., Yabe, D., & Seino, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13005 · Cited by 20
Han, J. D. J., Fei, Y., Zhou, F. L., Chen, X., Zhang, Y., Liu, L., & Fu, J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14107 · Cited by 20
“GLP-1 stimulates insulin release in a glucosedependent manner and plays an important physiological role in nutrient metabolism and glucose homeostasis (Evers et al., 2017).”
BackgroundNESTOR, J. J. J., Zhang, X., Jaw‐Tsai, S., Parkes, D. G., & Becker, C. (2021) · Peptide Science · doi:10.1002/pep2.24221 · Cited by 24
Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.08.009 · Cited by 21
Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists
Jiang, N., Jing, L., Li, Q., Su, S.-B., Yang, Q., Zhou, F. L., Chen, X., Han, J. D. J., Tang, C., & Tang, W. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113118 · Cited by 20
Design of Xenopus GLP-1-Based Long-Acting Dual GLP-1/Y2 Receptor Agonists
Yang, Q., Tang, W., Sun, L., Yan, Z., Tang, C., Yuan, Y., Zhou, H., Zhou, F. L., Zhou, S., Wu, Q., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01385 · Cited by 23
Yang, Q., Zhou, F. L., Tang, X., Wang, J., Feng, H., Jiang, W., Jin, L., Jiang, N., Yuan, Y., Han, J. D. J., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114214 · Cited by 18
Han, J. D. J., Chen, X., Zhao, L., Fu, J., Sun, L., Zhang, Y., Zhou, F. L., & Fei, Y. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00336 · Cited by 17
Kweon, S., Park, S. J., Lee, H. K., Kang, S. H., Chang, K.-Y., Choi, J. U., Park, J., Shim, J., Park, J. W., & Byun, Y. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s442617 · Cited by 16
“5,6 However, it is essential to note that simply extending half-life does not ensure superior diabetes treatment efficacy.”
BackgroundDrug discovery approaches targeting the incretin pathway
Deng, X., Tavallaie, M. S., Sun, R., Wang, J., Cai, Q., Shen, J., Lei, S., Fu, L., & Jiang, F. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103810 · Cited by 15
An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice
Ma, T., Lu, W., Wang, Y., Qian, P., Tian, H., Gao, X., & Yao, W. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174635 · Cited by 14
Li, M., Falk, B. T., Lu, X., Schroder, R. V., McCoy, M. A., Xu, W., Yin, D., Gindy, M. E., D’Addio, S. M., & Su, Y. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00449 · Cited by 14
Quiñones, M., Fernø, J., Diéguez, C., Nogueiras, R., & Al–Massadi, O. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1583642 · Cited by 14
“cutaneous administration in DIO mice doubled the body weight loss induced by liraglutide [111].”
BackgroundDiscovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist
Yuan, Y., Yan, Z., Lao, Q., Jiang, N., Wu, S., Lu, Q., Han, J. D. J., & Zhao, S. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115036 · Cited by 14
Demartis, A., Lahm, A., Tomei, L., Beghetto, E., Biasio, V. D., Orvieto, F., Frattolillo, F., Carrington, P. E., Mumick, S., Hawes, B. E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18494-5 · Cited by 13
Eriksson, O., Velikyan, I., Haack, T., Bossart, M., Evers, A., Lorenz, K., Laitinen, I., Larsen, P. J., Plettenburg, O., Johansson, L., et al. (2021) · Diabetes · doi:10.2337/db20-1096 · Cited by 13
“Details of the assay procedure are given in detail in the Supplementary Material and have been described previously (14,28).”
MethodSelf-citationCamacho, R. C., You, S.-H., D’Aquino, K. E., Li, W., Wang, Y., Gunnet, J. W., Littrell, J. B., Qi, J. S., Kang, L., Jian, W., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1794687 · Cited by 13
Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes
Eriksson, O., Velikyan, I., Haack, T., Bossart, M., Laitinen, I., Larsen, P. J., Berglund, J. E., Antoni, G., Johansson, L., Pierrou, S. E., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.213306 · Cited by 13
Self-citationChen, T., Sun, T., Bian, Y., Pei, Y., Feng, F., Chi, H., Li, Y., Tang, X., Sang, S., Du, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01456 · Cited by 11
Tinsley, I. C., Borner, T., Swanson, M. L., Chepurny, O. G., Doebley, S. A., Kamat, V., Sweet, I. R., Holz, G. G., Hayes, M. R., Jonghe, B. C. D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00185 · Cited by 11
Han, C., Sun, Y., Yang, Q., Zhou, F. L., Chen, X., Wu, L., Sun, L., & Han, J. D. J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00995 · Cited by 12
Palani, A., Nawrocki, A. R., Orvieto, F., Bianchi, E., Mandić, E., Pessi, A., Huang, C., Deng, Q., Toussaint, N., Walsh, E., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00217 · Cited by 12
Han, J. D. J., Meng, T., Chen, X., Han, Y., Fu, J., Zhou, F. L., Fei, Y., & Li, C. (2019) · The FASEB Journal · doi:10.1096/fj.201801479r · Cited by 11
Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates
Eriksson, O., Velikyan, I., Haack, T., Bossart, M., Evers, A., Laitinen, I., Larsen, P. J., Plettenburg, O., Takano, A., Halldin, C., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51530-0 · Cited by 11
Self-citationWang, S., Liu, Y., Yan, Z., Huang, X., Liao, Y., Tang, C., Jing, L., Zhou, Z., Han, J. D. J., Tang, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02032 · Cited by 10
Han, J. D. J., Fu, J., Sun, L., Han, Y., Mao, Q., Liao, F., Zheng, X., & Zhu, K. (2017) · MedChemComm · doi:10.1039/c7md00471k · Cited by 10
Jiang, N., Su, D., Chen, D., Huang, S., Tang, C., Jing, L., Yang, C.-Y., Zhou, Z., Yan, Z., & Han, J. D. J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01049 · Cited by 10
Cai, X., Li, C., Zhou, J., Dai, Y., Avraham, Y., Sun, L., Liu, C., Tong, J., Wang, Y., Bi, X., et al. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103538 · Cited by 11
Evers, A., Pfeiffer‐Marek, S., Bossart, M., Elvert, R., Lorenz, K., Heubel, C., Garea, A. V., Schroeter, K., Riedel, J., Stock, U., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000052 · Cited by 9
Self-citationGut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
Wolff, M., Schüler, A., Gast, K., Seckler, R., Evers, A., Pfeiffer‐Marek, S., Kurz, M. E., Nagel, N., Haack, T., Wagner, M., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01195 · Cited by 9
Self-citationWolff, M., Gast, K., Evers, A., Kurz, M. E., Pfeiffer‐Marek, S., Schüler, A., Seckler, R., & Thalhammer, A. (2021) · Biomolecules · doi:10.3390/biom11091305 · Cited by 8
“A stably folded conformation analogous to that of the Trp-cage miniprotein can be induced by addition of TFE in exendin-4 and Dual-Cex (Figure 9 and [5]), as demonstrated by a shift of the maximum Trp fluorescence to around 340 nm, indicating that Trp25 is not fully solvent exposed.”
BackgroundMethodSelf-citationHan, J. D. J., Fu, J., Yang, Q., Zhou, F. L., Chen, X., Li, C., & Yin, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112389 · Cited by 9
Design of a novel long-acting dual GLP-1/GIP receptor agonist
Dong, Y., Zhang, J., Xu, H., Shen, H., Lu, Q., Feng, J., & Cai, Z. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117630 · Cited by 7
Tasma, Z., Siow, A., Harris, P. W. R., Brimble, M. A., Hay, D. L., & Walker, C. S. (2025) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14916 · Cited by 7
“34,35,52,54,55 Alternatively, the literature describes a singular peptide that has affinity at two closely related receptors, in a similar fashion to PACAP 6-38 antagonizing both the PAC 1 and VPAC 2 receptors.”
Graham, G. V., Conlon, J. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173101 · Cited by 7
Velikyan, I., Bossart, M., Haack, T., Laitinen, I., Estrada, S., Johansson, L., Pierrou, S. E., Wagner, M., & Eriksson, O. (2022) · Pharmaceuticals · doi:10.3390/ph16010061 · Cited by 6
“The details of the cell line and potency assay procedure have been described previously [25,26].”
MethodSelf-citationWu, Y., Ji, T., Lv, J., & Wang, Z. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118025 · Cited by 6
Wagner, M., Doverfjord, J. G., Tillner, J., Antoni, G., Haack, T., Bossart, M., Laitinen, I., Johansson, L., Pierrou, S. E., Eriksson, O., et al. (2020) · Pharmaceuticals · doi:10.3390/ph13080176 · Cited by 6
Self-citationJiménez-Martí, E., Hurtado-Genovés, G., Aguilar-Ballester, M., Martínez‐Hervás, S., & Navarro, H. G. (2022) · Nutrients · doi:10.3390/nu14183775 · Cited by 7
“Although, in diabetic db/db mice, both SAR425899 and liraglutide agonists showed similar effects on glycemic control evaluated as a decrease in the glycosylated hemoglobin, HbA1c, levels [50].”
BackgroundInfluentialWu, B., Falsey, J. R., Netirojjanakul, C., Herberich, B., Holder, J. R., Sham, K. K. C., Aral, J., Forsythe, N., Walker, K. W., Lu, S.-C., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00032 · Cited by 4
Li, Q., Yang, Q., Han, J. D. J., Xiaohan, L. I. U., Fu, J., & Yin, J. (2022) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(22)60196-1 · Cited by 4
Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists
Zhang, X., Cai, Y., Yao, Z., Chi, H., Li, Y., Shi, J., Zhou, Z., & Sun, L. (2023) · Peptides · doi:10.1016/j.peptides.2023.170948 · Cited by 6
Rega, M., Petraglia, F. M., D’Ursi, L., Buonocore, M., Criscuolo, D., & Santoro, A. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2010005 · Cited by 2
Dakhnevich, A. Y., Miasoutova, S., Iliushin, D., Rozanov, A., & Ivanov, R. A. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1737987 · Cited by 2
“Until recently, ncAAs were only incorporated into proteins and peptides by chemical synthesis (Evers et al., 2017).”
Roles of Conformations on Predictions of Peptide Properties
Sindhikara, D., & Johnston, J. M. (2022) · ACS symposium series · doi:10.1021/bk-2022-1417.ch004 · Cited by 2
A novel thrombin-based triagonist with diabetes-protective and weight-lowering potential
Zhang, J., Zhang, Z., Ma, C., Zeng, L., Zhang, Y., Wang, P., & Xu, L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117853 · Cited by 2
New advances and novel approaches in obesity pharmacotherapy
Vaamonde, J. G., Frühbeck, G., & Salvador, J. (2018) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2018.08.003 · Cited by 1
Glucagon receptor modulation: Its role in diabetes care
Seshadri, K., Sosale, A., Kumar, K. M. P., Reddy, S. C., & CHAWLA, P. M. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_106_23 · Cited by 1
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Self-citationChepurny, O. G., Liles, A. N., Cham, N., Matsoukas, M., Liapakis, G., Meng, Q., Cooney, R. N., Doyle, R. P., & Holz, G. G. (2025) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2025.114745
“…through a process of hybridization in which select amino acid sequence motifs present within hormones and neuropeptides are intermixed (Chepurny et al., 2018; Coskun et al., 2018; Day et al., 2009; Evers et al., 2017; Gault et al., 2013; Han et al., 2021; Jiang et al., 2021; Yuan et al., 2023).”
Nordin, N., Choi, J., Lee, J., Kim, E.-H., RYU, E. K., Ryu, K., Lee, D., Hwang, E., Bang, J. K., & Cheong, H. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.6c01139
Metadata
- Authors
- Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., Lorenz, K., Kadereit, D., & Wagner, M.
- Affiliations
- Sanofi (Germany) (DE)
- Corresponding author
- Evers, Andreas
- Wagner, Michael
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-05-05
- Volume
- 60
- Issue
- 10
- Pages
- 4293-4303
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2608961189
- Semantic Scholar
- 8ff8b2b1e17044871e0c448672ec26ec4184b9c4
- Cited by
- 101
- References
- 47
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 14 · 2021: 10 · 2020: 22 · 2019: 18 · 2018: 16 · 2017: 3
- FWCI
- 13.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- exendin-4, GLP-1 receptor agonists, glucagon receptor agonist, dual receptor agonist, diabesity, structure-based design, structure-activity relationship, unnatural amino acids, modified amino acids, peptide stability, blood glucose reduction, db/db mice, diet-induced obesity, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Amino Acid Sequence, Animals, Blood Glucose, Body Weight, Female, Glucagon, Hypoglycemic Agents, Mice, Inbred C57BL, Mice, Obese, Obesity, Peptides, Structure-Activity Relationship, Swine, Venoms, Drug Design, Glucagon-Like Peptide 1, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.